A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients

INTRODUCTION: Sorafenib has demonstrated single agent activity in non-small cell (NSCLC) and small cell lung cancer (SCLC). Carboplatin/pemetrexed (CbP) and cisplatin/etoposide (PE) are commonly used in the treatment of these diseases. METHODS: A phase I trial escalating doses of sorafenib in combin...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Davies, Janine M., Dhruva, Nirav S., Walko, Christine M., Socinski, Mark A., Bernard, Stephen, Hayes, D. Neil, Kim, William Y., Ivanova, Anastasia, Keller, Kimberly, Hilbun, Layla R., Chiu, Michael, Dees, E. Claire, Stinchcombe, Thomas E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2978774/
https://ncbi.nlm.nih.gov/pubmed/20580118
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lungcan.2010.05.022
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados